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ABSTRACT 
 
Background 
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is a fast, 
easy-to-administer and already widely validated neuropsychological battery for cognition in 
multiple sclerosis. 
Objective 
The goals of our study were to validate the BICAMS in a Belgian Dutch-speaking population 
and to investigate to what extent including extensive versions of two of the three BICAMS 
subtests improved its psychometric qualities. 
Methods 
Ninety-seven persons with MS and ninety-seven healthy controls were included and group-
matched on age, education level and gender. All participants performed the BICAMS with an 
extensive version of the CVLT-II and BVMT-R. 
Results 
The SDMT and BVMT-R were able to dissociate between the MS and healthy control group, 
while the CVLT-II was not. Distributions of CVLT-II scores suggest learning effects in the 
MS group, indicating the need for alternative word lists or the construction of an adapted 
version fitted for repeated administration. Including the full CVLT-II and BVMT-R did not 
markedly improve the psychometric qualities of the BICAMS.  
Conclusion 
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This study validates the BICAMS in a Belgian Dutch-speaking population and facilitates the 
use of it in clinical practice, while providing evidence that including full versions of the 
CVLT-II and BVMT-R does not increase its psychometric qualities markedly. 
Keywords 
Multiple sclerosis; cognition; BICAMS. 
 
1. Introduction 
 
Multiple sclerosis (MS) is a disease characterized by inflammatory demyelination and 
neurodegeneration causing a wide range of physical and cognitive problems. Cognitive 
impairment (CI) is very common in MS, with prevalence rates ranging from 43% to 70% 
(Peyser et al., 1990; Rao et al., 1991). Particularly information processing speed (Van 
Schependom et al., 2014), working memory (D’Esposito et al., 1996), attention and 
visuospatial abilities (Chiaravalloti and DeLuca, 2008) have been shown to be affected in 
persons with MS (PwMS). These cognitive problems have a detrimental effect on the 
employment status, social and vocational activities, and mental health of PwMS. 
Currently, the most commonly applied neuropsychological test batteries are the Brief 
Repeatable Battery of Neuropsychological tests (BRB-N) (Rao et al., 1991)
 
and the Minimal 
Assessment of Cognitive Function in MS (MACFIMS) (Benedict et al., 2002), which have 
shown great sensitivity (e.g. Strober et al., 2009). However, these test-batteries are time-
demanding (45 and 90 minutes respectively), require a trained neuropsychologist and may be 
confounded by possible practice effects, making them unsuited for everyday practice.  
To address this issue, the Brief International Cognitive Assessment for Multiple Sclerosis 
(BICAMS) (Benedict et al., 2012; Langdon et al., 2012)
 
was designed. Consisting of three 
tests, carefully selected based on psychometric properties and ease of administration, the 
BICAMS can be administered by staff members without any prior neuropsychological 
training in about 15 minutes. 
The Symbol Digit Modalities Test (SDMT) (Smith, 1968) is thought to measure 
information processing speed (IPS) and one of the first cognitive functions to become 
impaired in MS (Van Schependom et al., 2014). The SDMT has been included in multiple 
batteries for cognitive impairment in MS (Benedict et al., 2002; Rao et al., 1991).  The ease 
and short duration of the SDMT administration as well as the possibility to perform the test 
orally make it an ideal test to assess IPS in MS, considering effects of fatigue and reduced 
fine motor skills. Memory function is also frequently impaired in MS (Thornton and Raz, 
1997). Although studies disagreed whether the mechanism underlying memory dysfunction 
was inadequate retrieval or initial learning, recent evidence supports the latter (DeLuca, 
Barbieri-Berger, & Johnson, 1994; John DeLuca, Leavitt, Chiaravalloti, & Wylie, 2013).  
The California Verbal Learning Test-II (CVLT-II) is a measure of verbal learning and 
memory, and has repeatedly shown high sensitivity and specificity for memory deficits in MS 
(Strober et al., 2009), even when using only the first two of the five learning trials
 
(Gromisch 
et al., 2013).  
Finally, visuospatial memory has been frequently found to be impaired in MS (Benedict 
et al., 2006; Rao et al., 1991). The Brief Visuospatial Memory Test Revisited (BVMT-R)
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(Benedict, 1997) displayed high sensitivity and specificity for visual learning and memory 
deficits in MS (Benedict et al., 2006) and was also included in the BICAMS.  
The BICAMS has already been translated and validated in Argentina (Vanotti et al., 
2016), Brazil
 
(Spedo et al., 2015), Canada (Walker et al., 2016), Czech Republic (Dusankova 
et al., 2012), Greece (Polychroniadou et al., 2016), Hungary
 
(Sandi et al., 2015), Iran 
(Eshaghi et al., 2012), Ireland (O’Connell et al., 2015), Italy (Goretti et al., 2014) and 
Lithuania (Giedraitiene et al., 2015). The goal of this study was to translate and validate the 
BICAMS in a Dutch-speaking Belgian population, according to the international standards 
for validation defined by Benedict and colleagues (2012). In addition, we will provide 
normative data corrected for age, gender and education level for a Dutch-speaking Belgian 
population. 
 
2. Material and methods 
2.1 Study population 
In total, 97 MS patients and 97 healthy controls were included in the study. MS patients were 
recruited from the National MS Center Melsbroek and the Revalidation and MS Center 
Overpelt in Belgium. Healthy controls were recruited from friends or relatives of MS 
participants and from the personnel at the MS Center Melsbroek. Healthy controls did not 
have experience with the tests included in the BICAMS. Criteria for inclusion were: (1) 
fluent in Dutch; (2) aged between 18 and 65; (3) able to provide written informed consent. 
Exclusion criteria were: (1) relapse in the last month before assessment; (2) 
neuropsychological screening in the last three months before the assessment; (3) neurological 
disorders other than MS that influence cognitive functioning (e.g. dementia or brain injury); 
(4) psychiatric disorders that could influence cognitive performance; (5) sensory or motor 
problems that could influence cognitive test performance. Participants did not receive any 
form of compensation. 
 
2.2 Ethics 
The study was approved by the ethics committee of the MS Center Melsbroek, Revalidation 
and MS Center Overpelt and University Hospital Brussels.  
 
2.3 NP assessment  
One examiner at each site was trained in order to ensure uniform administration, data 
recording and scoring. An MS-specialized nurse at the National MS Center Melsbroek, a PhD 
student at the Revalidation and MS Center Overpelt and a neuropsychologist at the 
University Hospital Brussels administered the neuropsychological tests. In order to be able to 
assess the added psychometric value of the full tests over the short versions included in the 
BICAMS, a full or extended version of the CVLT-II and BVMT-R was performed.  
 
2.4 Neuropsychological tests 
The SDMT is a measure of information processing speed, visual scanning and to a lesser 
extent working memory. Subjects are presented with nine symbols that are paired with the 
numbers one to nine. Subjects are asked to verbally respond with the paired digits as quickly 
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as possible when presented with a pseudo-random sequence of symbols. The outcome 
measure of the SDMT is the amount of correct responses in 90 seconds.  
In the CVLT-II, subjects have to recall word lists, which allows evaluation of verbal 
learning and memory. The examiner reads a list (list A) of 16 words, which subjects have to 
recall. This is repeated five times, each time with a repetition of list A. The measured 
outcome is the total number of words recalled over the five trials. The full version of the 
CVLT includes the recall of a second list (list B) after the first five trials, after which recall of 
list A is reassessed (short recall). Additionally, delayed recall (free recall and cued recall) and 
recognition (yes/no, forced choice) is assessed after 25 minutes. A Dutch translation of the 
CVLT-II was used.  
The BVMT-R is a test of visuospatial learning and memory in which subjects have to 
reproduce six abstract figures in a 2 x 3 grid. Subjects are given 10 seconds to memorize the 
figures and their location in the grid, after which they are asked to reproduce the figures with 
pencil and paper, without a time limit. This is repeated for three trials. Each drawing is 
assigned a score of 0, 1 or 2 based on criteria of accuracy and positioning of the six figures. 
In the full version of the BVMT-R, delayed recall and recognition of the figures is assessed 
after 25 minutes. 
In addition, depression and fatigue were assessed using Beck’s depression Inventory 
(BDI) (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961; Benedict, Fishman, McClellan, 
Bakshi, & Weinstock-Guttman, 2003) and Fatigue Scale for Motor and Cognitive Functions 
(FSMC) (Penner et al., 2009), both validated for Multiple Sclerosis. All tests were 
administered in a standardized order: (1) trial 1-3 of the BVMT-R; (2) trial 1-5, list B and 
short recall trials of the CVLT-II; (3) delayed recall and recognition trials of the BVMT-R; 
(4) SDMT; (5) BDI; (6) recall and recognition trials of the CVLT-II. 
Delays between the first and short recall trials and the delayed recall and recognition 
trials of the CVLT-II and BVMT-R were approximately 25 minutes. These delays were, 
however, prone to individual differences, which could possibly have an influence on the 
sensitivity of the full versions of the CVLT-II and BVMT-R. 
 
2.5 Statistical analysis 
All statistical analyses were performed using R (R Core Team, 2016). Wilcoxon-Mann-
Whitney, Chi-squared and t-tests were used for group comparisons. Regression-based norms 
were calculated in accordance with previously described procedures for MACFIMS 
(Parmenter et al., 2010). A statistical significance level of .05 was used and p-values were 
adjusted using Benjamini–Hochberg’s procedure in order to correct for multiple comparisons. 
Inter-quartile ranges (IQR) were calculated using linear interpolation of modes. Cohen’s d 
was calculated as effect size for parametric tests, while effect size r was calculated for non-
parametric tests (Field, 2005). 
 
3. Results  
 
3.1 Study participants 
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Demographic characteristics of the MS and HC group are presented in Table 1. Healthy 
controls were matched to PwMS on age, education level and gender. A comparison with 
populations from other BICAMS validation studies can be found in Additional Table 1.  
 
Table 1. Demographic data of study sample 
 
MS (n = 97) HC (n = 97) p 
  Age (M ± SD) 45.42 ± 9.24 43.52 ± 12.69 .41 
  Gender (men/women) 29/68 22/75 .33 
  Schooling level (M ± SD) 14.28 ± 1.86 14.69 ± 1.61 .33 
  BDI (M ± SD) 10.26 ± 7.47 4.67 ± 4.06 <.001 
  EDSS (M ± SD) 3.50 ± 2.50   
  Disease duration (M ± SD) 12.97 ± 7.16   
  Disease type       RRMS 
 PPMS 
 SPMS 
84% 
4% 
12% 
  
M = mean; SD = standard deviation; BDI = Beck’s Depression Inventory; EDSS = Expanded Disability Status 
Scale; RRMS = relapsing-remitting MS; PPMS = primary progressive MS; SPMS = secondary progressive MS. 
 
3.2 BICAMS validity 
The raw scores of the HC and MS group were compared in order to validate the three 
BICAMS tests. Table 2 presents the mean raw scores for each test. The MS group performed 
significantly worse than the HC group on the SDMT and BVMT-R, corresponding to a, 
respectively, moderate to large and small effect size. No significant difference was found 
between the MS group and the HC group on the five recall trials of the CVLT-II. When 
inspecting the distributions of test scores using the Beanplots (Kampstra, 2008) in Figure 1, 
we observe a general shift downwards in the scores of the MS group compared to the HC 
group.  For the CVLT-II, a minimal downwards shift in the 75
th
 and 100
th
 percentile is 
noticeable for the MS group. The BVMT-R scores, finally, show a minimal downwards shift 
(of 1 point) in the 25
th
 and 50
th
 (median) percentile and a large shift (of >3 points) of the 75
th
 
and 100
th
 percentile in the MS group.  
When comparing the extended BVMT-R, or the sum of the first three and the delayed 
recall trials, a significant difference between the MS group and the HC group with a medium 
to large effect size was observed. For the extended CVLT-II, the total of all recall trials was 
calculated as well as the recall discriminability index d’. This index was proposed in a study 
by Donders & Nienhuis (2007) and takes the amount of intrusions into account. Using both 
the total of all recall trials and the discriminability index d’, no significant difference between 
the MS and HC group was observed in CVLT-II performance. 
Table 2. Group performances on BICAMS and alternative measures 
 HC (n = 97) MS (n = 97) p effect size 
SDMT (M ± SD) 60.95 ± 10.21 52.11 ± 13.11 < .001 d = .752 
CVLT-II (Md, IQR) 63, [56 – 68] 64, [54 – 70] .573 rES = .013 
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Mean (M) or median (Md) raw scores and standard deviations (SD) or inter-quartile ranges (IQR) per group 
for each BICAMS measure and the alternative measures. Effect sizes calculated are Cohen’s d (small: .200, 
medium: .500, large: .800) or effect size rES (small: .100, medium: .300, large: .500). SDMT = Symbol Digit 
Modalities Task; CVLT-II = California Verbal Learning Task II; BVMT-R = Brief Visuospatial Memory Test 
Revisited; d’ = recall discriminability. 
 
 
 
 
 
 
3.3 Regression-based norms 
Based on Parmenter et al. (2010), we provide regression based norms using (1) a conversion 
table (Table 3) from raw scores to scaled scores (M = 10, SD = 3) based on the cumulative 
frequency distributions from the HC group and (2) regression models for each BICAMS test 
(Table 4) based on data from our HC group. These regression models allow the calculation of 
a predicted (scaled) score based on the demographic data of each subject using the following 
formula (example for SDMT):  
 
     ̂                                     
                    
                                          
 
BVMT-R (Md, IQR) 29, [25 – 32] 28, [21 – 31] .007 rES = .188 
CVLT-II Full (Md, IQR) 123, [108 - 131] 122, [104 - 132] .442 rES = .010 
CVLT-II d’ (Md, IQR) .62, [-.27 – 1.21] .23, [-.98 – 1.16] .124 rES = .092 
BVMT-R Full (Md, IQR) 38, [33 – 43] 31, [26 – 41] < .001 rES = .307 
Figure 1. Beanplots illustrating the distributions of raw scores in the two groups for the three BICAMS 
measures.  Bold horizontal lines reflect the 0, 25
th
, 75
th
 and 100
th
 percentile of the raw score distributions. For the 
SDMT, the bold red line represents the mean raw score for each group. For the CVLT-II, and BVMT-R, the bold red 
line represents the median raw score for each group. Density shapes are based on the normal density trace. Plots were 
made using the ‘beanplot’ package in R (Kampstra, 2008). SDMT = Symbol Digit Modalities Task; CVLT-II = 
California Verbal Learning Task II; BVMT-R = Brief Visuospatial Memory Test Revisited. 
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Using this formula and the coefficients from Table 4 we can, for example, calculate 
the predicted SDMT score of a 42-year old female (male: gender = 1; female: gender = 2) 
MS patient with a bachelor’s degree (15 years of education):  
 
                                                                
 
We can then convert the patient’s actual score on the SDMT (for example 51) to a 
scaled score (7) using Table 3, which allows us to calculate the difference between the 
predicted and actual score. A z-score can be calculated by dividing the difference between the 
predicted scaled score and the actual scaled score by the standard error of the residual (RSE) 
of the regression model (Table 4). In our example, this leads to a z-score of -1.514 ((7 - 
11.223) / 2.790). 
   
                       ̂     
       
 
 
 
Table 3. Conversion table: raw to normative scores. 
Scaled 
score 
SDMT CVLT-II BVMT-R 
2 36-38 <39 <17 
3 38-40 39-41 17-18 
4 41-43 42-45 19 
5 44-47 46-48 20-21 
6 48-50 49-51 22-23 
7 51-54 52-54 24 
8 55-57 55-58 25-26 
9 58-60 59-61 27-28 
10 61-64 62-64 29 
11 65-67 65-67 30-31 
12 68-71 68-70 32-33 
13 72-74 71-74 34-35 
14 75-77 75-77 36 
15 78-81 >78  
16 82-84   
17 85-88   
18 >88   
 
Conversion of raw scores of the three BICAMS measures to normative scores (M = 10, SD = 3), based on 
the cumulative distribution of 97 healthy controls. SDMT = Symbol Digit Modalities Task; CVLT-II = 
California Verbal Learning Task II; BVMT-R = Brief Visuospatial Memory Test Revisited. 
Table 4. Regression models of the three BICAMS measures. 
 Predictor Coefficient ß Standard 
error ß 
T p Adjusted 
R2 
RSE 
SDMT Intercept 10.648 3.869 2.753 .007 .135 2.790 
 Age -.289 .190 -1.519 .132   
 Age2 .002 .002 1.064 .290   
 Gender -.050 .694 -.073 .942   
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 Education .479 .190 2.524 .013   
CVLT-II Intercept 9.052 3.894 2.324 .022 .124 2.801 
 Age -.230 .191 -1.199 .234   
 Age2 .002 .002 .966 .337   
 Gender 2.182 .699 3.124 .003   
 Education .323 .191 1.692 .094   
BVMT-R Intercept 16.902 3.873 4.364 <.001 .133 2.793 
 Age -.473 .190 -2.484 .015   
 Age2 .005 .002 2.107 .038   
 Gender -1.427 .695 -2.054 .043   
 Education .341 .190 1.789 .076   
SDMT = Symbol Digit Modalities Task; CVLT-II = California Verbal Learning Task II; BVMT-R = Brief 
Visuospatial Memory Test Revisited. RSE = Residual Standard Error 
 
3.4 Relationships with other variables 
Figure 2 displays the relationships of PwMS’ performance on the three BICAMS subtests 
with age, EDSS, BDI and FSMC scores. The most remarkable findings are that the CVLT-II 
does not correlate significantly with age, and depression (assessed with BDI) and cognitive 
and motor fatigue (assessed with FSMC) only correlate significantly with SDMT scores. 
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Figure 2. Correlations of the three BICAMS subtests with age, physical disability, depression and 
fatigue. Correlation coefficients (r) are presented in the upper right corner, with significance marks: * p < 
.05, ** p < .01, *** p < .001. Darker dots mark overlapping data points. Grey area illustrates the 95% 
confidence interval using a linear model. SDMT = Symbol Digit Modalities Task; CVLT-II = California 
Verbal Learning Task II; BVMT-R = Brief Visuospatial Memory Test Revisited; BDI = Beck’s 
Depression Inventory; EDSS = Expanded Disability Status Scale; FSMC = Fatigue Scale for Motor and 
Cognitive Functions. 
 
 
4. Discussion 
 
The BICAMS is a reliable, neuropsychological screening battery for cognition in MS which 
has been validated in several languages and countries. It has major advantages over other 
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neuropsychological batteries by being very fast and easy to administer, making it less tiring 
for patients who very often have complaints of fatigue, and easier for small MS centres 
without a large neuropsychological staff to assess the cognitive status of their patients. 
Our validation study provides evidence for the psychometric characteristics of two of the 
three BICAMS measures, the SDMT and BVMT-R, and a possible explanation and solution 
for the lack thereof in the CVLT-II in a Belgian Dutch-speaking population. In addition, 
using the extended versions of the CVLT-II and BVMT-R, as used in the MACFIMS battery 
(Benedict et al., 2002) does not improve the psychometric properties of the BICAMS test to a 
large extent. Normative data for use of the BICAMS in a Belgian Dutch-speaking population 
is also provided. 
When comparing our study sample of patients and controls with regard to age, gender 
balance, education level and EDSS scores to that of other validation studies, the average age 
appears to be higher than what is found in the majority of studies (Additional Table 1). 
Similar to the findings in the Czech BICAMS validation study (Dusankova et al., 2012), the 
SDMT and BVMT-R scores showed the largest differences between the MS and HC group.  
Interestingly, the SDMT scores in the MS group show a general downward shift (see Fig. 
1) while the BVMT-R scores display an asymmetric downward shift with the 75
th
 and 100
th
 
percentile of the MS group scores showing larger differences than the 25
th
 and 50
th
 or median 
percentile. This phenomenon could be explained by recent findings by Van Schependom and 
colleagues (2014) who showed that visuospatial memory and learning gets impaired in later 
stages of the disease compared to IPS, which is thought to be the first and also most widely 
affected cognitive domain in MS. Taking this into account, the asymmetric downward shift in 
BVMT-R scores of the MS group compared to the HC group could be interpreted as a 
subpopulation that has started to show problems in visuo-spatial memory while the a larger 
subpopulation does not yet show these problems. The more general shift in SDMT scores of 
the MS group suggests that the largest part of them is already displaying problems with 
information processing speed.  
Remarkably, our two groups did not show any significant difference in CVLT-II scores. 
Figure 1 illustrates that besides a reasonable number of MS patients that score very low (i.e. 
impaired), most MS patients seem to score better on the CVLT-II than the HC group. This is 
confirmed by a slightly higher 50
th
, 75
th
 and 100
th
 percentile score for the MS group 
compared to the HC group. This was surprising and in contrast with every BICAMS 
validation study until present (Dusankova et al., 2012; Eshaghi et al., 2012; Giedraitiene et 
al., 2015; Goretti et al., 2014; O’Connell et al., 2015; Polychroniadou et al., 2016; Sandi et 
al., 2015; Spedo et al., 2015; Vanotti et al., 2016; Walker et al., 2016). We would like to 
argue that this might be a consequence of learning effects, as there is a large potential for 
learning in the CVLT-II. First, the 16 words are repeated a large number of times (especially 
in the full version of the CVLT-II) so it is not impossible that subjects remember the words 
long after the test was acquired. Second, there is an optimal strategy that subjects can 
discover: semantic clustering. The 16 words can be organised in four semantic categories. It 
has been well known for a long time in cognitive psychology that organisation improves 
short-term information storage (for review see Mandler, 1967). Important for this is that in 
the (short and long delay) cued trials of the full CVLT-II, subjects are explicitly instructed to 
recall the words per category. Therefore, subjects who have performed the full version of the 
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CVLT-II only once might already benefit by knowing that there are four categories and that 
semantic clustering might help them. A possible explanation to why other studies do not find 
these learning effects might be that the full version of the CVLT-II is a very frequently 
administered test in the recruiting centres, known as centres for multidisciplinary treatment 
and rehabilitation for people with MS in Belgium, that participated in this study. This might 
not have been the case for the other validation studies. This explanation is supported by the 
fact that the CVLT-II scores of our MS group are remarkably high compared to other 
validation studies (Additional Table 1). Unfortunately, no data is available on how many 
times participants were administered the BICAMS subtests. In light of these findings, we 
would like to stress the need for alternative word lists for the CVLT-II, similar to the 
different SDMT forms that are available, or the construction of an adapted version which is 
fitted for repeated administration. 
Using the full version of the CVLT-II (rES = .092), as used in the MACFIMS, only 
marginally increased the difference in scores between the two groups compared to the short 
version (rES = .013). The full version of the BVMT-R (rES = .307) did yield better effects than 
the shorter BICAMS-version (rES = .188), which leads to a cost-benefit discussion. While the 
full BVMT-R would be able to assess cognition more completely, this test would take 
significantly longer (25 min. waiting time and about 5 min. of delayed recall trials) than the 
short version. Hence, including the full BVMT-R would abolish one of the main advantages 
of the BICAMS; that it can be administered in only 15 minutes. Therefore, we advise to keep 
the current composition of the BICAMS as a screening tool and to utilize more extensive 
batteries such as the MACFIMS (Benedict et al., 2002) or NSBMS (Rao et al., 1991) when 
more detailed cognitive assessments are required. 
Finally, performance of the MS group on the SDMT and BVMT-R correlated 
significantly with age, as did all three subtests with physical disability (EDSS). Age, 
considering the difficulty of determining disease onset in MS, and physical disability can 
both be interpreted as a reflection of disease severity. In addition, the SDMT was the only 
test that correlated with depression (BDI) and cognitive and motor fatigue (FSMC). The 
former could be related to effects of treatment with antidepressants and is consistent with 
some previous findings (Arnett, 2005; Landrø et al., 2004; Vanotti et al., 2016) although 
some studies did not find this relationship (O’Connell et al., 2015). The latter makes sense as 
the SDMT is a test with a time limit and fatigue is well known to influence processing speed 
(Diamond et al., 2008). 
Although the delays between the first and short recall trials and the delayed recall and 
recognition trials of the CVLT-II and BVMT-R were approximately 25 minutes (as 
recommended by Langdon et al., 2012), a possible limitation could be the inter-subject 
differences in delays, due to some subjects needing more or less time to complete the 
intermediate tests. It is possible that subjects who are cognitively impaired need more time 
for those tests and – therefore – experience a longer delay (and thus a disadvantage) in the 
administration of delayed recall and recognition trials. A final limitation could be the sample 
size. Although we included significantly more subjects (97) than recommended by Benedict 
et al. (2012) to validate the BICAMS and the effect size favourably compares to similar 
validation studies (see Additional Table 1), a larger control sample could strengthen the 
presented results. 
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5. Conclusion 
 
In this study, we aimed to validate the BICAMS, a screening battery for cognition in MS that 
is fast, easy-to-use and already widely-validated, in a Belgian Dutch-speaking population. 
We provide evidence for the psychometric qualities of two of the three BICAMS tests: the 
SDMT and BVMT-R. The CVLT-II failed to dissociate between MS patients and healthy 
controls, in contrast to previous BICAMS validation studies. We argue that this is a 
consequence of learning effects, illustrated by the score distributions in both groups. 
Therefore, the construction of alternate CVLT-II forms or test procedures is strongly 
advocated.  
In addition, we showed that using the extended versions of the CVLT-II and BVMT-R 
tests does not notably improve the psychometric qualities of these tests as neuropsychological 
screening tools in MS.  
Finally, we provide normative data for the use of the BICAMS in a Belgian Dutch-
speaking population. 
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Additional Table 1. Population characteristics and scores of main BICAMS validation studies. 
    
Populati
on size 
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e 
(M 
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SD
)  
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er          
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(M ± 
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(M ± 
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(M 
± 
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T-II       
(M ± 
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T-R     
(M ± 
SD) 
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1.6 
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± 9.7 
28.2 
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Dusankova 
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134 
34 
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14 ± 
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65 ± 
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60 ± 
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29 ± 
4 
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± 
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50 ± 
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52 ± 
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23 ± 
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Giedraitien
e et al. 
(2015) 
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57 ± 
11.5 
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M = Mean; SD = Standard Deviation; N.A. = data not available; RR = Relapsing-Remitting; SP = Secondary Progressive; PP 
= Primary Progressive; PR = Progressive-Relapsing; SDMT = Symbol Digit Modalities Task; CVLT-II = California 
Verbal Learning Task II; BVMT-R = Brief Visuospatial Memory Test Revisited.  
 
Highlights 
 This study validates the BICAMS in a Belgian Dutch-speaking population 
 Including full versions of the CVLT-II and BVMT-R does not increase performance 
 MS patients and HCs show differences on the SDMT and BVMT-R but not on the 
CVLT-II 
 CVLT-II scores of MS patients suggest strong learning effects 
 
 
